denosine is an endogenous nucleoside that has potent electrophysiologic effects.1-4 As an antiarrhythmic agent, adenosine has several unique properties: 1) it is an intermediate metabolite (Figure 1) , 2) it has a very short half-life (less than 1.5 seconds), 3) its effects are mediated by specific membrane receptors coupled to guanine nucleotide binding proteins (G proteins), and 4) it has sitespecific actions in the myocardium with important differential effects in supraventricular and ventricular tissue. ' Adenosine also has an important role in regulating the myocardial oxygen supply-demand balance. Adenosine achieves this by increasing oxygen supply through coronary vasodilation and by reducing oxygen demand by decreasing myocardial contractility, antagonizing the effects of catecholamines, and depressing automaticity and conduction within the sinus and atrioventricular (AV) nodes. ' Recently, the United States Food and Drug Administration approved the use of adenosine for therapy of paroxysmal supraventricular tachycardia (PSVT), the first clinical application of adenosine. The purpose of this review is to present a rational approach for the therapeutic applications of adenosine for cardiac arrhythmias based on an understanding of its cellular and integrative mechanisms of action.
Source of adenosine. Adenosine is formed by dephosphorylation of adenosine monophosphate (AMP) (ATP pathway, Figure 2 , panel 1), catalyzed by the enzyme 5'-nucleotidase. This enzyme is mostly bound to cell membranes (ecto-5'-nucleotidase) in the heart but is also present in the cytosol (cytosolic 5'-nucleotidase). Therefore, adenosine can be formed either intracellularly or extracellularly by the degradation of AMP. Because all the enzymes required for the degradation of adenosine triphosphate (ATP) and AMP can be found extracellularly, adenine nucleotides released from platelets and endothelial cells are also potential sources of adenosine. Extracellular cyclic AMP (cAMP) can also lead to the formation of adenosine, which may be an important source of the nucleoside during f3-adrenergic stimulation. 8 In addition to the ATP pathway, adenosine can be formed intracellularly by the degradation of S-adenosylhomocysteine (SAH), catalyzed by the enzyme S-adenosylhomocysteine hydrolase (SAH pathway, Figure 2 , panel 1). The relative contribution of each metabolic pathway to the formation of adenosine varies according to the experimental conditions. For example, in normoxic hearts a significant fraction of adenosine is derived from the SAH pathway, whereas during hypoxia the ATP pathway is the main source of adenosine. 9 Receptor-effector complex. Adenosine binds to specific cell surface receptors (intracellular adenosine is transported out of the cell), which in turn triggers a series of reactions that lead to activation of effector units such as membrane ionic channels ( Figure 2 , panel 2). The adenosine receptor-effector coupling system (Figure 3 ), its activation, and the associated cardiac responses are discussed in detail below.
Removal of adenosine. The actions of adenosine can be terminated by enzymatic metabolism and by adenosine receptor antagonists (e.g., alkylxanthines) ( Figure 2, panel 3 ). The nucleoside can be either deaminated by adenosine deaminase to inosine, which is mostly inactive, or phosphorylated by adenosine kinase to AMP. Since both adenosine deaminase and adenosine kinase are cytosolic enzymes, adenosine must first be taken up by the cells, by either simple or facilitated diffusion via a nucleoside transport system. This nucleoside transport system is ubiquitous (e.g., present in endothelial cells, erythrocytes, and cardiomyocytes) and can be inhibited by Figure 3) .
Characterization of the adenosine A1 receptor from bovine and chick heart membranes by photoaffinity labeling indicates that it is a polypeptide with a molecular weight of 35-37. 6 Cardiac Actions ofAdenosine In the heart, in addition to causing coronary vasodilation, adenosine depresses sinoatrial (SA) node activity, AV nodal conduction, atrial contractility, and ventricular automaticity. Adenosine also attenuates the cardiac stimulatory actions of catecholamines and the release of norepinephrine from nerve terminals.1,3' Furthermore, adenosine inhibits oxygen metabolite generation by activated neutrophils and stimulates glycolysis.132 It is worth noting that the cardiac actions of adenosine are remarkably similar to those of the neurotransmitter acetylcholine (ACh). Both ACh and adenosine produce the same cardiac effects and share similar receptor-effector coupling systems (Figure 3 ). It appears, therefore, that a major role of ACh and adenosine, in addition to their direct effects (see below), is to function in parallel to oppose the cardiac stimulatory actions of the sympathetic neurotransmitters norepinephrine and epinephrine. Electrophysiologic Effects Adenosine A, receptor-mediated actions in the heart are essentially of two types, those that are cAMPindependent (direct effects) and others that are cAMPdependent (indirect or antiadrenergic effects).
Similar to other inhibitory receptors (e.g., the muscarinic receptor), the adenosine A, receptor is coupled to its effector units (i.e., ionic channels and adenylyl cyclase) via Continuous infusion of adenosine (150-300 ,ug/ kg/min) in anesthetized patients maintains controlled hypotension and is associated with a decrease in systemic vascular resistance, an increase in cardiac output, and a moderate increase in heart rate. Since venous tone is relatively unaffected, right atrial and pulmonary capillary wedge pressures are unchanged.55 In contrast to its effects in anesthetized patients, infusion of adenosine (140 ,tg/kg/min) in conscious subjects has no effect on mean arterial pressure since systolic pressure increases by 10% and diastolic pressure decreases by 6%. The sympathoadrenal system appears to be activated by adenosine since heart rate and plasma norepinephrine and epinephrine levels increase in a dose-dependent manner.56 These effects are not observed in patients with dysautonomia, suggesting that adenosine's hemodynamic effects are not mediated by direct vascular effects but rather by autonomic reflex activation (e.g., carotid body chemoreceptors). For instance, adenosine has a pressor effect when infused proximal to the carotid arteries but lowers pressure when OUT IN infused into the descending aorta.53 Activation of carotid body chemoreceptors by adenosine is also thought to stimulate respiration and produce respiratory alkalosis.57 It is noteworthy that carotid body chemoreceptor reflexes are attenuated during anesthesia, perhaps accounting for the absence of a pressor response as previously noted.55
Cardiac Electrophysiology
Sinus node. Bolus doses of adenosine have a biphasic effect on heart rate. An initial period of sinus bradycardia, observed within 20 seconds after injection and lasting less than 10 seconds, is followed by sinus tachycardia. The latter response is likely due to adenosine's stimulation of carotid body chemoreceptors, resulting in respiratory stimulation and secondary activation of pulmonary stretch receptors.53,58 Adenosine has been proposed as a putative mediator of the sick sinus syndrome59 due to its direct negative chronotropic effect on the sinus node, reversal of symptomatic bradycardia by the adenosine receptor antagonist theophylline,60 and depression of sinus node automaticity by purinergic compounds in patients with sick sinus syndrome.6' Although this is a provocative hypothesis, it lacks experimental support.
Atrium. Limited data are available regarding the effects of adenosine in human atria. Consistent with experimental findings, adenosine shortens action potential duration and refractoriness.62 These effects may precipitate atrial flutter or fibrillation and is the mechanism by which nucleoside transport blockers like dipyridamole induce atrial flutter that is reversed by aminophylline. 63 AV node. Adenosine slows conduction within the AV node (negative dromotropy), which can result in transient AV block.54,64 Intracardiac recordings demonstrate that heart block is preceded by prolongation of the A-H interval, effects that are unaltered by atropine. Reversal of adenosine-induced slowing of AV nodal conduction by aminophylline is not affected by propranolol, suggesting that competitive antagonism of adenosine by aminophylline rather than aminophylline-induced release of catecholamines from adrenergic nerve terminals or the adrenal medulla is the operative mechanism.64 These findings are clinically relevant since aminophylline has been shown to restore AV conduction in patients with AV block complicating an inferior myocardial infarction.65 This observation raises the possibility that endogenous adenosine may mediate some clinical electrophysiologic effects (negative dromotropy) under conditions of oxygen supply-demand imbalance. Recently, dipyridamole, which elevates endogenous adenosine levels, was shown to significantly slow conduction across the AV node.63 This finding suggests that endogenous adenosine can also have electrophysiologic effects under normoxic conditions in the presence of specific pharmacologic perturbations.
His-Purkinje system. Adenosine has little, if any, direct effect on the His-Purkinje system. Conduction (H-V interval) is unaltered by adenosine.fr Furthermore, unlike observations in guinea pig15 and canine67 hearts, adenosine does not diminish His-Purkinje automaticity in humans under basal conditions.52 However, adenosine does have potent antiadrenergic effects (i.e., it attenuates the effects of catecholamine stimulation). For example, in patients with complete heart block, adenosine reverses isoproterenol-induced acceleration of the ventricular escape rate.52
Accessory pathway. Most anterograde and retrograde accessory pathways are insensitive to adenosine. However, pathways that demonstrate unusual conduction properties, that is, decremental conduction, respond to adenosine.68 The likely explanation is that most accessory pathways comprise normal atrial fibers with resting membrane potentials near the potassium equilibrium potential EK (-90 mV). Therefore, the membrane-stabilizing effects of adenosine have little effect in these tissues. In contrast, decremental conduction pathways may comprise partially depolarized atrial tissue with a resting membrane potential of less than -70 mV. These tissues would therefore be expected to respond to adenosine-induced hyperpolarization. Therapeutic Effects Sinus node. Adenosine causes transient slowing of sinus tachycardia due to its hyperpolarizing membrane effect and antagonism of the catecholamine effects on the pacemaker current (IF). Adenosineinduced hyperpolarization likely accounts for the termination of tachycardia due to sinus node reentry in a recent case report. 69 Atium. Adenosine has been reported in general to have no effect on atrial cycle length in atrial fibrillation, atrial flutter, and intra-atrial reentry,54,70 although rare exceptions are known.71 Automatic atrial tachycardia and multifocal atrial tachycardia have not been systematically studied with adenosine. Preliminary data suggest that adenosine may transiently suppress automatic atrial tachycardia72 but more often has no effect.73 '74 The one reported patient with multifocal atrial tachycardia did not respond to adenosine. 73 AV node. Adenosine is nearly always effective in terminating supraventricular tachycardia in which the AV node forms part of the reentrant circuit.75 These arrhythmias include AV nodal reentry and orthodromic AV reciprocating tachycardia. In the latter case, the anterograde limb consists of the atrium, AV usually associated with a structurally normal heart. The mechanism of tachycardia in these patients is postulated to be due to catecholamine-induced delayed afterdepolarizations. Afterdepolarizations arise during phase 4 of the action potential and are dependent on intracellular calcium overload. Adenosine is thought to terminate these tachycardias by inhibiting adenylyl cyclase through an inhibitory G protein (antiadrenergic effect) (Figure 3 ). This transduction process results in decreased intracellular production of cAMP, protein phosphorylation, and entry of calcium into the cell. Other perturbations that directly or indirectly decrease intracellular calcium (i.e., calcium channel blockers, /3-blockers, and vagal maneuvers51,77) usually also terminate the arrhythmia. Several points are worth emphasizing. Catecholamine facilitation of ventricular tachycardia due to reentry does not appear to respond to adenosine. This may be because adenosine has little or no effect on isoproterenol-induced action potential changes in K'-depolarized ischemic guinea pig ventricles or in infarcted Purkinje fibers.7778 Fi- nally, adenosine appears to be effective only in triggered activity due to stimulation of cAMP. For example, adenosine is ineffective in ouabain-induced triggered activity, in which calcium overload is mediated by inhibition of Na,K-ATPase and not stimulation of cAMP.66 Based on these observations, adenosine may prove to be an important probe for differentiating ventricular tachycardia due to cAMPmediated triggered activity from reentry, automaticity, and other forms of triggered activity.
Diagnostic Uses
In addition to its therapeutic benefit, adenosine has considerable diagnostic utility for distinguishing the mechanism of narrow and wide complex tachycardias (Figures 4 and 5 ). This is due to its relatively site-specific effects, short half-life, and minimal hemodynamic consequences. In narrow complex tachycardia, for instance, adenosine is useful in distinguishing between atrial tachycardias and those that require the AV node as part of the reentrant circuit. For possibly reentrant rhythms confined to the sinus node) (Figure 4) .
In patients with wide complex tachycardia ( Figure  5 ), adenosine, unlike verapamil,79 does not usually cause hypotension or acceleration of the tachycardia.71,76 Adenosine either terminates aberrant PSVT (due to AV nodal reentry or AV reciprocating tachycardia) or results in transient AV block (supraventricular tachycardia due to atrial tachycardia).
Unlike verapamil, adenosine causes no hemodynamic deterioration when given to patients with atrial flutter/fibrillation that conducts anterogradely over an accessory pathway. The mean R-R interval is unaltered, although the shortest R-R decreases by approximately 10%.76 This finding is consistent with the recent observation that adenosine may shorten refractoriness in the accessory pathway by at least 20 msec,80 an effect that may be related to an increase in sympathetic tone.
Preliminary findings in a single patient suggest that Mahaim fibers that give rise to decremental AV or atriofascicular pathways (and wide complex tachycardia), an uncommon etiology for preexcitation, are also sensitive to adenosine. 81 Purinergic compounds including adenosine also have a role in identifying patients with intermittent or latent preexcitation. By slowing conduction or producing block in the AV node, preexcitation may become manifest.82-85 Seldom, however, patients with prolonged86 or even normal anterograde refractory periods of the accessory pathway87 show sensitivity to purinergic compounds.
Finally, caution should be exercised in patients with preexcitation who have AV reciprocating tachycardia. Precipitation of atrial fibrillation by adenosine could potentially result in rapid AV conduction over the accessory pathway. Adenosine Versus Verapamil Two retrospective studies have analyzed the relative efficacies of adenosine and verapamil in terminating PSVT. Adenosine had a slightly higher success rate and was associated with milder symptoms.88,89 A nonblinded prospective protocol comparing the two agents in the same patients with inducible supraventricular tachycardia showed similar efficacy rates. 81 Termination of the arrhythmia with adenosine was often followed by atrial or ventricular premature complexes, although no sustained arrhythmias occurred. The largest study comparing the two agents to date was a randomized, prospective study involving 125 patients. 90 Patients initially received either adenosine (6 mg) or verapamil (5 mg), followed by 12 mg or 7.5 mg, respectively, if the initial dose was unsuccessful in terminating the tachycardia. Cumulative efficacy rates were approximately 90% with either drug. Postconversion arrhythmias were equal in both groups. Spontaneous reinitiation of supraventricular tachycardia was more frequent with adenosine, although this ilar efficacy results were also observed in studies comparing ATP and verapamil.91 '92 The advantages of adenosine with respect to verapamil include faster onset of action (less than 30 seconds versus 1-2 minutes), absence of adverse hemodynamic effects, short half-life, and transient duration of side effects and bradyarrhythmias. The relative disadvantages of adenosine may include frequent recurrence of arrhythmia (which may be initiated by premature complexes triggered by adenosine) and a higher incidence of side effects, albeit well tolerated.
Adenosine Versus ATP It was originally proposed that the electrophysiologic effects of ATP were in part due to its vagomimetic activity since in dogs, atropine and vagotomy attenuate the chronotropic and dromotropic effects of ATP.93 However, more recent data indicate that the electrophysiologic effects of ATP in the human heart are not attenuated by atropine.64 The observation that the effects of ATP are blocked by methylxanthines and potentiated by dipyridamole suggest that such actions are those of adenosine, generated by the degradation of ATP.6494
There is one double-blind, randomized study comparing adenosine and ATP.95 Clinical efficacy for the diagnosis and termination of supraventricular tachycardia, onset and offset of action, molar potency, and the incidence and severity of side effects were similar for both compounds. The effective dose range for both compounds was 2.5-20 mg. The major advantage of adenosine over ATP is the former's stability at room temperature. Fifty percent of ATP is degraded by 2 months when it is stored at room temperature, whereas adenosine is stable at 2 months. 95 Dosage and Interactions Adenosine is available in sterile saline for intravenous administration. For optimal therapeutic results, it is obligatory that adenosine be delivered as a rapid bolus followed by a saline flush. If administered as a slow bolus, adenosine's electrophysiologic effects may not be manifest. Adenosine's half-life in the blood pool is less than 1.5 seconds,96 and it is rapidly metabolized by endothelial cells and erythrocytes. Its myocardial actions are therefore due to first-pass effects. Factors such as site of injection, circulation time, and central volume determine the amount of adenosine that will reach its target site.
Myocardial effects from a peripheral route are manifest within 30 seconds,90 whereas adenosine's effects from central access are usually apparent in 10-20 seconds.68,70 Due to its rapid metabolism and resolution of side effects, intervals between boluses can be 60 seconds. A 6 mg i.v. bolus is the recommended initial dose and has an efficacy rate of 60% for PSVT. A 12 mg i.v. dose has an efficacy rate of approximately 90%. 90 .Due to differences in individual sensitivities to the drug, an alternative dose-ranging protocol can be difference did not achieve statistical significance. Simbased on body weight. For instance, one can start with an initial dose of 50 1g/kg and increment it by 50 ,ug/kg until PSVT is terminated or side effects become intolerable. This method may reduce the incidence of side effects and would be the preferred approach in children, in whom the mean effective dose is approximately 100-150 1,g/kg.73
Precautions should be taken in patients who are taking dipyridamole. The adenosine dose should be reduced to one fourth of the usual dose since dipyridamole potentiates the effects and half-life of adenosine. 63 Patients who are taking competitive antagonists such as theophylline or caffeine may require larger than usual doses of adenosine, although doses as high as 19 mg have been ineffective in patients on theophylline. 70 In heart transplant patients who develop PSVT, the adenosine dose should be reduced to one third to one fifth of the usual dose due to denervation-induced supersensitivity to the drug. 97 Caution should be exercised in treating patients with high-grade AV block since the degree of block may be temporarily exacerbated by adenosine. Similarly, adenosine may also cause prolonged sinus pauses in patients with sick sinus syndrome.
Adverse Effects
Cumulative clinical side effects occur in about 30% of patients.90 Due to adenosine's rapid clearance from the blood, these symptoms last less than 60 seconds. The most common symptoms are facial flushing (due to cutaneous vasodilation), dyspnea, and chest pressure. Adenosine is thought to 
